Outcomes in COVID-19 molnupiravir studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 77% 0.23 [0.01-5.69] 0/140 1/62 77% improvement All studies 77% 0.23 [0.01-5.69] 0/140 1/62 77% improvement 1 molnupiravir COVID-19 study c19mp.com Sep 24, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 0.89 Effect extraction pre-specified Favors molnupiravir Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 77% 0.23 [0.01-5.69] 0/140 1/62 77% improvement All studies 77% 0.23 [0.01-5.69] 0/140 1/62 77% improvement 1 molnupiravir COVID-19 mortality result c19mp.com Sep 24, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 0.89 Favors molnupiravir Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) -33% 1.33 [0.14-12.5] hosp. 3/140 1/62 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment -33% 1.33 [0.14-12.5] 3/140 1/62 -33% improvement All studies -33% 1.33 [0.14-12.5] 3/140 1/62 -33% improvement 1 molnupiravir COVID-19 hospitalization result c19mp.com Sep 24, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 0.25 Favors molnupiravir Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 77% 0.23 [0.01-5.69] 0/140 1/62 77% improvement All studies 77% 0.23 [0.01-5.69] 0/140 1/62 77% improvement 1 molnupiravir COVID-19 serious outcomes c19mp.com Sep 24, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 0.89 Effect extraction pre-specified Favors molnupiravir Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 49% 0.51 [0.22-1.18] viral+ 10/118 9/54 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 49% 0.51 [0.22-1.18] 10/118 9/54 49% improvement All studies 49% 0.51 [0.22-1.18] 10/118 9/54 49% improvement 1 molnupiravir COVID-19 viral clearance result c19mp.com Sep 24, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 1.58 Favors molnupiravir Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 77% 0.23 [0.01-5.69] 0/140 1/62 77% improvement All studies 77% 0.23 [0.01-5.69] 0/140 1/62 77% improvement 1 molnupiravir COVID-19 Randomized Controlled Trials c19mp.com Sep 24, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 0.89 Effect extraction pre-specified Favors molnupiravir Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 77% 0.23 [0.01-5.69] 0/140 1/62 77% improvement All studies 77% 0.23 [0.01-5.69] 0/140 1/62 77% improvement 1 molnupiravir COVID-19 RCT mortality result c19mp.com Sep 24, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 0.89 Favors molnupiravir Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Fischer (RCT) 65% 0.35 [0.01-8.33] death 0/55 1/62 Fischer (RCT) 67% 0.33 [0.01-8.03] death 0/62 1/62 Fischer (RCT) 58% 0.42 [0.02-10.0] death 0/23 1/62 Fischer (RCT) -33% 1.33 [0.14-12.5] hosp. 3/140 1/62 Fischer (RCT) -13% 1.13 [0.07-17.6] hosp. 1/55 1/62 Fischer (RCT) -100% 2.00 [0.19-21.5] hosp. 2/62 1/62 Fischer (RCT) 58% 0.42 [0.02-10.0] hosp. 0/23 1/62 Fischer (RCT) 49% 0.51 [0.22-1.18] viral+ 10/118 9/54 Fischer (RCT) 89% 0.11 [0.01-0.86] viral+ 1/53 9/54 Fischer (RCT) 30% 0.70 [0.25-1.93] viral+ 5/43 9/54 Fischer (RCT) -9% 1.09 [0.37-3.18] viral+ 4/22 9/54 Fischer (RCT) 92% 0.08 [0.01-0.62] viral+ 1/117 6/54 Fischer (RCT) 92% 0.08 [0.00-1.34] viral+ 0/53 6/54 Fischer (RCT) 91% 0.09 [0.00-1.48] viral+ 0/42 6/54 Fischer (RCT) 59% 0.41 [0.05-3.20] viral+ 1/22 6/54 Fischer (RCT) 30% 0.70 [0.37-1.36] viral+ 19/137 12/61 Fischer (RCT) 62% 0.38 [0.13-1.12] viral+ 4/53 12/61 Fischer (RCT) -8% 1.08 [0.54-2.18] viral+ 13/61 12/61 Fischer (RCT) 56% 0.44 [0.11-1.83] viral+ 2/23 12/61 molnupiravir COVID-19 outcomes c19mp.com Sep 24, 2021 Favors molnupiravir Favors control
Please send us corrections, updates, or comments.
Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC .
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
